AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02830880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI, CT, or Bone Scan
Description: Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
Study NCT04048915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long live drama
Description: The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.
Study NCT04048915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short live drama
Description: The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.
Study NCT01892358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SKIN Intervention
Study NCT01892358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Study NCT02631330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity
Description: Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
Study NCT01464476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: Azimilide 75 mg. Once daily, oral administration
Study NCT01464476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo. Once daily, oral administration
Study NCT04096911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200 mg intravenously every 3 weeks
Study NCT04096911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quadrivalent HPV vaccine
Description: The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
Study NCT02805777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: A new vent CPAP mask system will be used in this trial
Study NCT02787863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar-13
Description: Conjugate 13 serotype pneumococcal vaccine
Study NCT02787863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo-23
Description: Polysaccharide 23-valent pneumococcal vaccine.
Study NCT01368835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera treatment
Description: treatment of cheeks and upper neck area of face
Study NCT01700556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Manager
Description: The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity).
Study NCT01700556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistive Technologies
Description: The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
Study NCT01700556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: light support
Description: An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
Study NCT01700556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 preventive home visits by a nurse
Description: The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
Study NCT01396447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsules.
Study NCT01396447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study NCT01700556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 preventive home visits by a nurse
Description: The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
Study NCT02056483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening-based nurse navigation
Description: Screening-based nurse navigation for breast cancer rehabilitation
Study NCT02823977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Blinded study drug administered to experimental arm
Study NCT02823977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Open-label study drug administered to both arms
Study NCT02823977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Open-label study drug administered to both arms
Study NCT02823977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Blinded comparator administered to control arm
Study NCT00769002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluShield
Description: Flu vaccine
Study NCT00769002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluShield - same arm
Description: Flu vaccine
Study NCT00769002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluShield - opposite arm
Description: Flu vaccine
Study NCT00769002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draws
Description: 50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
Study NCT00769002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG PET-CT Scan
Description: PET scan
Study NCT00769002 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Cytokine Profiling
Description: Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
Study NCT05266937 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab,Paclitaxel, Carboplatin
Description: Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor).
Study NCT02148380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed plus carboplatin
Study NCT02148380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT01457807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241 ER formulation 1
Description: Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
Study NCT01457807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered with the same intervention scheme as intervention 1 and 2
Study NCT01457807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241 Alternative titration scheme with formulation 1 or 2
Description: 50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
Study NCT05086029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Superb Microvascular Imaging
Description: Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
Study NCT01493453 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine
Description: aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10\*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
Study NCT03867578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HR-MRI
Description: The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
Study NCT03867578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard CT Imaging
Description: Standard CT scans will be performed for preoperative imaging in all patients.
Study NCT03867578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
Study NCT03899779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face hypnotherapy
Description: 12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
Study NCT03899779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online hypnotherapy
Description: 12 weeks treatment with online hypnotherapy
Study NCT03899779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online psychoeducation
Description: 12 weeks treatment with online psychoeducation
Study NCT03991351 — intervention group
Intervention type: OTHER
Intervention: Exposure to images
Description: Exposure to images
Study NCT02101723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + Zn/Fe
Description: Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
Study NCT02101723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + Zn
Description: Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
Study NCT02101723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder without micronutrients
Study NCT03051555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/ CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
Study NCT02137564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma secretase inhibitor PF-03084014
Description: Given PO
Study NCT02137564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02137564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01309074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin-Lyrica
Description: Pregabalin in a dose up to 300mg/day in BID dosing.
Study NCT01309074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline in a dose up to 200mg/day in BID dosing.
Study NCT04091087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crisaborole ointment
Description: crisaborole ointment
Study NCT04091087 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: vehicle ointment
Description: vehicle ointment
Study NCT03458390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyGIeaCare colon irrigation
Description: PillCam COLON for visualization of bowel lining
Study NCT01117636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)
Description: Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
Study NCT01117636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
Study NCT01117636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
Study NCT01686620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-123
Study NCT01686620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro (Humalog)
Study NCT02363686 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FEES
Description: A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
Study NCT02363686 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: BSE
Description: Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
Study NCT05059496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching with Pressure Biofeedback Unit
Description: Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
Study NCT05059496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring stretching with out Pressure Biofeedback Unit
Description: Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
Study NCT00562549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-2101
Study NCT00562549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLx-2101
Study NCT00847912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped.
Study NCT00847912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, vehicle control
Description: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped.
Study NCT01617278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 1
Description: I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
Study NCT01617278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Colon
Description: High definition white light
Study NCT01617278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 2
Description: I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
Study NCT03434405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SocialMind
Description: SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
Study NCT03434405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT03434405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT04118816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: overnight polysomnography recording at least six hours
Study NCT04118816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency test
Description: daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
Study NCT04118816 — intervention group
Intervention type: OTHER
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure treatment for sleep-disordered breathing
Study NCT00820651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks